Home
Øystein Bruserud's picture

Øystein Bruserud

Emeritus
  • E-mailoystein.bruserud@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2017). Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism. Expert opinion on therapeutic targets. 357-369.
  • Show author(s) (2017). Mesenchymal stem cells support survival and proliferation of primary human acute myeloid leukemia cells through heterogeneous molecular mechanisms. Frontiers in Immunology. 1-17.
  • Show author(s) (2017). CDC25 inhibition in acute myeloid leukemia - A study of patient heterogeneity and the effects of different inhibitors. Molecules. 1-18.
  • Show author(s) (2016). The past, present and future subclassification of patients with acute Myeloid Leukemia. Current Pharmaceutical Biotechnology. 6-19.
  • Show author(s) (2016). Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients. Biological Procedures Online. 1-10.
  • Show author(s) (2016). Nutrition in allogeneic stem cell transplantion - Clinical guidelines and immunobiological aspects. Current Pharmaceutical Biotechnology. 92-104.
  • Show author(s) (2016). Myeloproliferative neoplasiar og JAK2-mutasjonar :. Tidsskrift for Den norske legeforening. 1889-1894.
  • Show author(s) (2014). En mann i 80-årene med muskelstivhet og hudblødninger 1058. Tidsskrift for Den norske legeforening. 1058-1061.
  • Show author(s) (2010). Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. European Journal of Haematology. 239-251.
  • Show author(s) (2010). Early pre-engraftment, functional, in vitro responsiveness of T lymphocytes in allotransplanted, acute leukemia patients: proliferation and release of a broad profile of cytokines, possibly predictive of graft-versus-host disease. European Cytokine Network. 40-49.
  • Show author(s) (2009). Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods. Transfusion.
  • Show author(s) (2009). The protein kinase C agonist PEP005 increases NF-kB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. British Journal of Haematology. 761-774.
  • Show author(s) (2009). Should low-dose mycophenolate mofetil be used to prolong the response after rituximab therapy in patients with immune thrombocytopenic purpura? A case report. Hematology. 224-226.
  • Show author(s) (2009). Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors; release profile and pharmacological modulaion. European Journal of Haematology. 239-251.
  • Show author(s) (2008). Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia. 287-293.
  • Show author(s) (2008). Platelet-released supernatants enhance hematopoietic stem cell proliferation in vitro. Platelets. 55-159.
  • Show author(s) (2008). In vivo biological effects of ATRA in the treatment of AML. Expert Opinion on Investigational Drugs. 1623-1633.
  • Show author(s) (2008). In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22. Journal of Interferon and Cytokine Research. 297-310.
  • Show author(s) (2008). Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood. 2866-2877.
  • Show author(s) (2007). The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology. 814-828.
  • Show author(s) (2007). The Immunological Dilemma: Cellular Innate and Adaptive Immune Response Versus Human Acute Myeloid Leukemia. The Open Hematology Journal. 1-14.
  • Show author(s) (2007). Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 332-341.
  • Show author(s) (2007). Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Molecular Cancer.
  • Show author(s) (2007). LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Molecular Cancer.
  • Show author(s) (2007). In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion. 653-665.
  • Show author(s) (2007). Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Current Pharmaceutical Biotechnology. 388-400.
  • Show author(s) (2007). Epigenetic targeting in acute myeloid leukemia: use of flow cytometry in monitoring therapeutic effects. Current Pharmaceutical Biotechnology. 401-411.
  • Show author(s) (2007). Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunology and Immunotherapy. 13-24.
  • Show author(s) (2007). Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. European Journal of Haematology. 210-225.
  • Show author(s) (2007). Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting. Leukemia Research. 1303-1313.
  • Show author(s) (2007). Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology. 199-207.
  • Show author(s) (2006). cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. International Journal of Oncology. 1065-1080.
  • Show author(s) (2006). T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunology and Immunotherapy. 830-840.
  • Show author(s) (2006). Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2 : Bax ratio and low levels of heat shock protein 70 and 90. Leukemia Research. 1531-1540.
  • Show author(s) (2006). Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia? Cancer Immunology and Immunotherapy. 221-228.
  • Show author(s) (2006). Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. Transfusion. 800-810.
  • Show author(s) (2006). A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clinical Cancer Research. 3985-3992.
  • Show author(s) (2005). The viability of cryopreserved PBPC depends on the DMSO concentration and the concentration of nucleated cells in the graft. Cytotherapy. 328-333.
  • Show author(s) (2005). Serum levels of angioregulatory mediators in healthy individuals depend on age and physical activity: studies of angiogenin, basic fibroblast growth factor, leptin and endostatin. Scandinavian Journal of Clinical and Laboratory Investigation. 505-511.
  • Show author(s) (2005). Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 631-646.
  • Show author(s) (2005). Large-volume leukapheresis yields more viable CD34+cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34+cells. Transfusion. 248-253.
  • Show author(s) (2005). In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serum. Journal of Cancer Research and Clinical Oncology. 377-384.
  • Show author(s) (2005). In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leukemia Research. 185-196.
  • Show author(s) (2005). Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels. European Journal of Haematology. 24-34.
  • Show author(s) (2000). The Cellular Immune system of Patients with Acute Leukemia and Severe Chemotherapy-Induced Leukopenia: Characterization of T Lymphocyte Subsets Responsive to IL-16 and IL-17. Acta Haematologica. 80-91.
  • Show author(s) (2000). Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels. Cancer Immunology and Immunotherapy. 377-387.
  • Show author(s) (2000). New strategies in the treatment of acute myelogenous leukemia: mobilization and transplantation of autologous peripheral blood stem cells in adult patients. Stem Cells. 343-351.
  • Show author(s) (2000). New strategies for the treatment of acute myelogenous leukemia: differentiation induction, present use and future possibilities. Stem Cells. 157-165.
  • Show author(s) (2000). Induction of differentiation and apoptosis - A possible strategy in the treatment of adult acute myelogenous leukemia. Oncologist. 454-462.
  • Show author(s) (2000). In vitro Culture of Human Acute Myelogenous Leukemia (AML) Cells in Serum-Free Media: Studies of Native AML Blasts and AML Cell Lines. Cellular Immunology. 136.
  • Show author(s) (2000). In vitro Culture of Human Acute Myelogenous Leukemia (AML) Cells in Serum-Free Media: Studies of Native AML Blasts and AML Cell Lines. Journal of Hematotherapy & Stem Cell Research. 923-932.
  • Show author(s) (2000). High dose ara-C combined with autologous perpherial blood stem cell transplantation in the treatment of acute myelogenous leukemia: the question is still not answered. Stem Cells. 459-460.
  • Show author(s) (2000). Effects of imipenem and cilastatin on human T-lymphocytes derived from acute leukemia patients with chemotherapy-induced leucopenia: studies of T-lymphocyte responses in the presence of acute myelogenous leukemia (AML) blast accessory cells. International Journal of Immunopharmacology. 69-81.
  • Show author(s) (2000). Cytokine responsiveness of mitogen-activated T cells derived from acute leukemia patients with chemotherapy-induced leukopenia. Journal of Interferon and Cytokine Research. 947-954.
  • Show author(s) (2000). Autologous stem cell transplantation as post-remision therapy in adult acute myelogenous leukemia: does platelet contamination of peripheral blood mobilized stem cell grafts influence the risk of leukemia relapse? Journal of Hematotherapy & Stem Cell Research. 433-443.
  • Show author(s) (1999). Serum levels of thrombopoietin and stem cell factor in acute leukemia patients with chemotherapy-induced cytopenia and complicating infections. Platelets. 17-23.
  • Show author(s) (1999). Insulin-like growth factor -1 (IGF-1) is a costimulator of the expansion of lineage committed cells derived from peripheral blood mobilized CD34+ cells in multiple myeloma patients. Hematology ASH Education Program. 217-229.
  • Show author(s) (1999). In vitro effects of insulin-like growth factor - 1 (IGF-1) on proliferation and constitutive cytokine secretion by acute myelogenous leukemia blasts. European Journal of Haematology. 191-198.
  • Show author(s) (1999). In vitro culture of acute myelogenous leukemia blasts: a comparison of four different culture media. Journal of Hematotherapy. 63-73.
  • Show author(s) (1999). Functional differentiation of acute myeloid leukaemia blast cells. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1023-1033.
  • Show author(s) (1999). Expression and release of adhesion molecules by human acute myelogenous leukemia blasts. Leukemia Research. 149-157.
  • Show author(s) (1999). Effects of y-Irradiation on Acute Myelogenous Leukemia Blasts: In Vitro Studies of Proliferation, Constitutive Cytokine Secretion, and Accessory Cell Function During T Cell Activation. Journal of Hematotherapy & Stem Cell Research. 431-441.
  • Show author(s) (1999). Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. Leukemia. 1175-1187.
  • Show author(s) (1998). T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation. Scandinavian Journal of Immunology. 54-62.
  • Show author(s) (1998). T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: Characterization of clonogenic T-cell proliferation. Scandinavian Journal of Immunology. 54-62.
  • Show author(s) (1998). Storcellet granulær lymfocyttleukemi. Tidsskrift for Den norske legeforening. 1045-1048.
  • Show author(s) (1998). Ribosomal proteins sustain morphology, function and phenotype in acute myeloid leukemia blasts. Leukemia Research. 329-339.
  • Show author(s) (1998). Ribosomal proteins sustain morphology, function and phenotype in acute myeloid leukemia blasts. Leukemia Research. 329-339.
  • Show author(s) (1998). Insulin-like growth factor-1 (IGF-1) has a costimulatory effect on proliferation of committed progenitors derived from human umbilical cord CD34+ cells. Stem Cells. 334-342.
  • Show author(s) (1998). IL-4, IL-10 and IL-13 in acute myelogenous leukemia. Cytokines, cellular & molecular therapy. 187-198.
  • Show author(s) (1998). Fremtidig behov for spesialister i blodsykdommer. Tidsskrift for Den norske legeforening. 2507-2510.
  • Show author(s) (1998). Effects of acute myelogenous leukemia blasts on platelet release of soluble P-selectin and platelet-derived growth factor. Platelets. 352-358.
  • Show author(s) (1998). Effect of acute myelogenous leukemia blasts on platelet release of soluble P-selectin and platelet-derived growth factor. Platelets. 352-358.
  • Show author(s) (1998). Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells. Cancer Immunology and Immunotherapy. 221-228.
  • Show author(s) (1997). Interleukin-13 secretion by normal and posttransplant T lymphocytes; in vitro studies of cellular immune responses in the presence of acute leukaem blast cells. Cancer Immunology and Immunotherapy. 45-52.
  • Show author(s) (1997). Interleukin 4 responses in acute leukemia patients with severe chemotherapy-induced leucopenia. European Journal of Haematology. 269-276.
  • Show author(s) (1997). Interleukin 4 responses in acute leukaemia patients with severe chemotherapy-induced leucopenia. European Journal of Haematology. 269-276.
  • Show author(s) (1997). Granulocyte-macrophage colony-stimulating factor (GM-CSF) in acute myelogenous leukemia; a review of present and possible future approaches for GM-CSF therapy. Cancer Journal. 310-314.
  • Show author(s) (1997). Effects of normal platelets on proliferation and constitutive cytokine secretion by human acute myelogenous leukaemia blasts. Platelets. 397-404.
  • Show author(s) (1996). Serum Levels of Adhesion Molecules and Cytokines in Patients with Acute Leukaemia. Leukemia and Lymphoma. 423-450.
  • Show author(s) (1996). Interleukin 1 receptor antagonist (IL1RA) in acute leukaemia: IL1RA is both secreted spontaneously by myelogenous leukaemia blasts and is a part of the acute phase reaction in patients with chemotherapyinduced leucopenia. European Journal of Haematology. 87-95.
  • Show author(s) (1995). In vitro effect of r-verapamil on acute myelogenous leukemia blast cells: studies of cytokine secretion and cytokine-dependent blast proliferation. Cancer Chemotherapy and Pharmacology. 70-78.
  • Show author(s) (1995). Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia. Leukemia. 1910-1920.
  • Show author(s) (1995). Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia. Leukemia. 1910-1920.
  • Show author(s) (1994). Serum Concentrations of tumor necrosis factor-_a during chemotherapy-induced leukophenia in patients with acute leukaemia and bacterial infections. Leukemia Research. 415-421.
  • Show author(s) (1994). Høydosebehandling med autolog stamcellestøtte ved maligne sykdommer. Tidsskrift for Den norske legeforening. 3115-3120.
  • Show author(s) (1994). HLA-DR Molecules are Restriction Elements for T Cell Recognition of Three Different Antigenic Epitopes on the Streptokinase Molecule. Journal of Clinical & Laboratory Immunology. 135-142.
  • Show author(s) (1993). Tumor specific antigens revisited: Presentation to the immune system of fusion peptides resulting solely from tumor specific chromosomal translocations. Oncology and Research. 315-320.
  • Show author(s) (1993). Secretion of IL-2, IL-3, IL-4, IL-6 and GM-CSF by CD4%+ and CD8%+ TCR_a_b%+ T-cell clones derived early after allogeneic bone marrow transplantation. Scandinavian Journal of Immunology. 65-74.
  • Show author(s) (1993). Secretion of IL-2, IL-3, IL-4, IL-6 and GM-CSF by CD4%+ and CD8%+ TCR_a_B%+ T-cell Clones derived early after allogeneic bone marrow transplantation. Scandinavian Journal of Immunology. 65-74.
  • Show author(s) (1993). IFN-_g and TNF-_a secretion by CD4%+ and CD8%+ TCR_a_B%+ T-cell clones derived early after allogeneic bone marrow transplantation. European Journal of Haematology. 73-79.
  • Show author(s) (1993). HLA-DR Molecules are Restriction Elements for T Cell Recognition of Three Different Antigenic Epitopes on the Streptokinase Molecule. Journal of Clinical & Laboratory Immunology.
  • Show author(s) (1993). Effects of dipyridamole and R-verapamil on in vitro proliferation of blast cells from patients with acute myelogenous leukemia. Leukemia Research. 507-513.
  • Show author(s) (1993). Effects of dipyridamole and R-verapamil on in vitro proliferation of blast cells from patients with acute myelogenous leukaemia. Leukemia Research. 507-513.
  • Show author(s) (1993). Cyclosporine A and FK506 show similar immunosuppressive effects on long-term in vitro T-cell proliferation. International Journal of Immunopharmacology. 93-97.
  • Show author(s) (1992). Tumor-specific antigens revisited: presentation to the immune system of fusion peptides resulting solely from tumor-specific chromosomal translocations. Oncology Res. 315-320.
  • Show author(s) (1992). The effect of disodium cramoglycate on in vitro proliferation of peripheral blood mononuclear cells from allergic and healthy donors. Scandinavian Journal of Immunology. 721-731.
  • Show author(s) (1992). The Effect of Disodium Cromoglycate on In Vitro Proliferation of Peripheral Blood Mononucular Cells from Allergic and Healthy Donors. Scandinavian Journal of Immunology. 721-732.
  • Show author(s) (1992). IL2- and IL4-dependent proliferation of T-cell clones derived early after allogeneic bone marrow transplantation: Studies of patients with chronic myelogeneous leukaemia. European Journal of Haematology. 221-227.
  • Show author(s) (1992). Effect of dipyridamole, theophyllamine and verapamil on spontaneous in vitro proliferation of myelogenous leukaemia cells. Acta Oncologica. 53-58.
  • Show author(s) (1992). Can dipyridamole or verapamil slow regrowth of leukaemia cells? Leukemia Research. 725-725.
  • Show author(s) (1992). CD4+ TCR_a_b+ T-cell clones derived shortly after allogeneic bone marrow transplantation: Theophyllamine and verapamil inhibit proliferation of functionally heterogeneous T-cells. International Journal of Immunopharmacology. 783-789.
  • Show author(s) (1992). At least five antigenic epitopes on the stretokinase molecule are recognized by human CD4+ TCR_a,_b+ T cells. Molecular Immunology. 1097-1104.
  • Show author(s) (1992). At least five antigenic epitopes on the streptokinase molecule are recognized by human CD4%+ TRC_a_bT cells. Molecular Immunology. 1097-1104.
  • Show author(s) (1991). Proliferative and cytotoxic function of T cell clones derived very early after allogeneic bone marrow transplantation. Bone Marrow Transplantation. 113-118.
  • Show author(s) (1991). CD4 TCR alpha/beta T cells developing after allogeneic bone marrow transplantation in patients with chronic myelogenous leukaemia. Dipyridamole inhibits functionally heterogenous T cell clones. International Journal of Immunopharmacology. 1127-1135.
Academic lecture
  • Show author(s) (2006). The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • Show author(s) (2006). The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • Show author(s) (2005). Discovering candidate genes that distinguish between CML and AML using microarrays.
  • Show author(s) (2003). Global gene expression profiling of human cancers using DNA microarray technology - examples, pitfalls and outlook.
  • Show author(s) (2003). Global analysis of gene expression and regulatory patterns in cancer.
  • Show author(s) (2003). Global analysis of gene expression and regulatory patterns in acute myeloid leukemia.
  • Show author(s) (2003). Flt3 ligand and its receptor in regulation of Hdm2 in acute myelogenous leukemia.
  • Show author(s) (2003). DNA microarray studies of human cancer - pitfalls and outlook.
  • Show author(s) (2002). Systemic regulation of angiogenesis in acute leukemia: Chemotheraphy induced modulation of angiogenin, basic fibroblast growth factor and endostatin serum levels is consistent with inhibition of angiogenesis.
  • Show author(s) (1998). Effect of platelet-derived growth factor on acute myelogenous leukemia blasts.
  • Show author(s) (1997). T lymphocyte functions in acute leukaemia patients with chemotherapy-induced leukopenia.
  • Show author(s) (1997). Effects of insuline-like growth factor (IGF-1) on proliferation and cytokine secretion by acute myelogenous leukemia blasts.
Academic anthology/Conference proceedings
  • Show author(s) (2009). Medikamentell kreftbehandling. Cytostikaboken. Cytokiner i kreftbehandlingen. Farmakologisk institutt, Det medisinske fakultet, Universitetet i Oslo.
Abstract
  • Show author(s) (2010). PRIMARY HUMAN AML CELLS CAN EXPRESS CALRETICULIN ON THE CELL SURFACE AND RELEASE HEAT SHOCK PROTEIN 70 (HSP70) AND HSP90 DURING APOPTOSIS. Haematologica. 496-497.
  • Show author(s) (2010). PRIMARY HUMAN ACUTE MYELOGENOUS LEUKEMIA CELLS RELEASE HEAT SHOCK PROTEIN (HSP) 70 AND HSP90 DURING APOPTOSIS. Experimental Hematology. S19-S20.
  • Show author(s) (2010). PHARMACOLOGICAL TARGETING OF THE PI3K-AKT/PKB-MTOR PATHWAY ALTERS LOCAL ANGIOREGULATION IN ACUTE MYELOGENOUS LEUKEMIA. Haematologica. 266-266.
  • Show author(s) (2010). OXYGEN LEVELS INFLUENCE THE CYTOKINE RELEASE PROFILE OF AML CELLS. Experimental Hematology. S119-S119.
  • Show author(s) (2010). Connexin expression by human primary AML cells. Blood. 887-887.
  • Show author(s) (2010). Combined epigenetic and signal transduction therapy modulate specific signal transduction patterns in acute myeloid leukemia. Haematologica. 510-510.
  • Show author(s) (2010). Circulating T Cells Derived From Patients with Low Risk Myelodysplastic Syndromes Show Altered Chemokine Receptor Expression. Blood. 1637-1638.
  • Show author(s) (2009). PRIMARY HUMAN ACUTE MYELOGENOUS LEUKEMIA CELLS SHOW CONSTITUTIVE RELEASE OF SEVERAL MATRIX METALLOPROTEASES AND THEIR INHIBITORS. Haematologica. 545-545.
  • Show author(s) (2008). FLT3 internal tandem duplication involving its libiquitin dependent endocytosis motif suspend modulation by HDM2 and are associated with inferior survival in AML. Haematologica. 10-10.
  • Show author(s) (2008). Evaluation of combinational therapy of MDM2-antagonist nutlin-3 and HDAC-inhibitor valproic acid in acute myeloid leukemia in vitro and in vivo. Blood. 1024-1024.
  • Show author(s) (2008). Chemokine receptor expression by circulating T cells derived from acute leukemia patients with severe chemotherapy-induced cytopenia express a wide range of chemokine receptors. Haematologica. 456-457.
  • Show author(s) (2007). The protein kinase C activator PEP005 increases the chemokine release in native acute myelogenous leukemia (AML) blasts. Experimental Hematology. 87-87.
  • Show author(s) (2007). Release of angiopoietin-1 by acute myelogenous leukemia (AML) cells is increased by stromal cells and associated with mutations in the nucleophosmin (NPM) gene. Experimental Hematology. 72-72.
  • Show author(s) (2007). Linking susceptibility to histone deactylase inhibitors and basal gene expression profiles in acute myeloid leukaemia. Experimental Hematology. 77-77.
  • Show author(s) (2007). In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts: The chemokine release profile of the AML dendritic cells depends on the experimental protocol. Haematologica. 485-485.
  • Show author(s) (2007). Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in the susceptibility to histone deacetylase inhibitors. Haematologica. 112-112.
  • Show author(s) (2007). Flt3 mutations in proximity to an ubiquitin dependent endocytosis motif suspend its Hdm2 modulation. Blood. 148B-148B.
  • Show author(s) (2006). cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. NBS-nytt. 106.
  • Show author(s) (2006). The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. International Journal of Molecular Medicine. S65.
Academic literature review
  • Show author(s) (2022). Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia. Molecules.
  • Show author(s) (2022). Hematopoiesis, Inflammation and Aging—The Biological Background and Clinical Impact of Anemia and Increased C‐Reactive Protein Levels on Elderly Individuals. Journal of Clinical Medicine.
  • Show author(s) (2021). Therapeutic use of valproic acid and all-trans retinoic acid in acute myeloid leukemia—literature review and discussion of possible use in relapse after allogeneic stem cell transplantation. Pharmaceuticals.
  • Show author(s) (2021). Cytokine release syndrome in the immunotherapy of hematological malignancies: The biology behind and possible clinical consequences. Journal of Clinical Medicine.
  • Show author(s) (2020). The implementation of mass spectrometry-based proteomics workflows in clinical routines of acute myeloid leukemia: Applicability and perspectives. International Journal of Molecular Sciences. 1-23.
  • Show author(s) (2020). Febrile neutropenia in acute leukemia. Epidemiology, etiology, pathophysiology and treatment. Mediterranean Journal of Hematology and Infectious Diseases (MJHID). 1-19.
  • Show author(s) (2019). Thrombotic complications in adult patients with severe single coagulation factor or platelet defects-|an overview. Expert Review of Hematology. 119-128.
  • Show author(s) (2019). Precision medicine for TP53-mutated acute myeloid leukemia. Expert Review of Precision Medicine and Drug Development. 263-274.
  • Show author(s) (2018). Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. Expert Review of Hematology. 13-24.
  • Show author(s) (2018). The possible importance of β3 integrins for leukemogenesis and chemoresistance in acute myeloid leukemia. International Journal of Molecular Sciences. 1-17.
  • Show author(s) (2018). Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia. Expert Opinion on Investigational Drugs. 377-387.
  • Show author(s) (2018). S100 proteins in acute myeloid leukemia. Neoplasia. 1175-1186.
  • Show author(s) (2018). Cytokines, adhesion molecules, and matrix metalloproteases as predisposing, diagnostic, and prognostic factors in venous thrombosis. Frontiers in medicine. 1-11.
  • Show author(s) (2017). Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies. Expert Opinion on Drug Discovery. 1053-1065.
  • Show author(s) (2017). Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers. Expert Review of Proteomics. 649-663.
  • Show author(s) (2017). Interleukin-6 in allogeneic stem cell transplantation: Its possible importance for immunoregulation and as a therapeutic target. Frontiers in Immunology. 1-15.
  • Show author(s) (2017). Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment. Expert Review of Clinical Immunology. 553-569.
  • Show author(s) (2016). The complexity of targeting PI3K-Akt-mTOR signalling in human acute myeloid leukaemia: The importance of leukemic cell heterogeneity, neighbouring mesenchymal stem cells and immunocompetent cells. Molecules. 32 pages.
  • Show author(s) (2016). Targeting of cell metabolism in human acute myeloid leukemia - more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling? European Journal of Haematology. 211-221.
  • Show author(s) (2016). Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. Cytotherapy. 172-185.
  • Show author(s) (2015). STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia. Expert Review of Hematology. 29-41.
  • Show author(s) (2015). Emerging therapeutic targets in human acute myeloid leukemia (part 2) – bromodomain inhibition should be considered as a possible strategy for various patient subsets. Expert Review of Hematology. 315-327.
  • Show author(s) (2015). Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication. Expert Review of Hematology. 299-313.
  • Show author(s) (2014). Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid Leukemia - The possibility to target several kinases through inhibition of the various CDC25 isoforms. Molecules. 18414-18447.
  • Show author(s) (2014). Heat shock protein 90 – a potential target in the treatment of human acute myelogenous leukemia. Advances in cancer drug targets. 3-53.
  • Show author(s) (2014). Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia? Expert opinion on therapeutic targets. 929-944.
  • Show author(s) (2014). Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: Immunological mechanisms and the results from clinical studies. Cancer Immunology and Immunotherapy. 757-777.
  • Show author(s) (2014). Akutt promyelocyttleukemi. Tidsskrift for Den norske legeforening. 1052-1055.
  • Show author(s) (2013). The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine-the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation. Toxins. 336-362.
  • Show author(s) (2013). Primær myelofibrose – patogenese, diagnostikk og behandling. Tidsskrift for Den norske legeforening. 1946-1950.
  • Show author(s) (2013). Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clinical Epigenetics.
  • Show author(s) (2012). The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. European Cytokine Network. 140-153.
  • Show author(s) (2012). Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia? Expert Opinion on Investigational Drugs. 587-603.
  • Show author(s) (2012). High-dose etoposide in allogeneic stem cell transplantation. Cancer Chemotherapy and Pharmacology. 765-782.
  • Show author(s) (2011). Untangling the intracellular signalling network in cancer - a strategy for data integration in acute myeloid leukemia. Journal of Proteomics. 269-281.
  • Show author(s) (2011). The chemokine system. in allogeneic stem-cell transplantation: a possible therapeutic target? Expert Review of Hematology. 563-576.
  • Show author(s) (2011). Future perspectives: therapeutic targeting of notch signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies. Bone Marrow Research.
  • Show author(s) (2011). Current practice and future directions for optimization of platelet transfusions in patients with severe therapy-induced cytopenia. Blood reviews. 113-122.
  • Show author(s) (2011). Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. Journal of Biomedicine and Biotechnology. 23 pages.
  • Show author(s) (2010). The chemokine system in experimental and clinical hematology. Current Topics in Microbiology and Immunology. 3-12.
  • Show author(s) (2010). The Crosstalk Between the Matrix Metalloprotease System and the Chemokine Network in Acute Myeloid Leukemia. Current Medicinal Chemistry. 4448-4461.
  • Show author(s) (2010). The Chemokine Network in Acute Myelogenous Leukemia: Molecular Mechanisms Involved in Leukemogenesis and Therapeutic Implications. Current Topics in Microbiology and Immunology. 149-172.
  • Show author(s) (2010). Connexin-based signaling in acute myelogenous leukemia (AML). Biochimica et Biophysica Acta - Biomembranes. 1-8.
  • Show author(s) (2010). Combination of Intensive Chemotherapy and Anticancer Vaccines in the Treatment of Human Malignancies: The Hematological Experience. Journal of Biomedicine and Biotechnology. 15 pages.
  • Show author(s) (2010). Clinical proteomics of myeloid leukemia. Genome Medicine.
  • Show author(s) (2009). Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opinion on Investigational Drugs. 433-455.
  • Show author(s) (2009). Heat shock protein 90-a potential target in the treatment of human acute myelogenous leukemia. Current Cancer Drug Targets. 761-776.
  • Show author(s) (2009). Granulocyttransfusjon. Tidsskrift for Den norske legeforening. 416-419.
  • Show author(s) (2009). Connexins are active participants of hematopoietic stem cell regulation. Stem Cells and Development. 807-812.
  • Show author(s) (2008). Review: genetic models of acute myeloid leukaemia. Oncogene. 3765-3779.
  • Show author(s) (2008). Platelet functions and clinical effects in acute myelogenous leukemia. Thrombosis and Haemostasis. 27-37.
  • Show author(s) (2008). Effects of benzene on human hematopoiesis. The Open Hematology Journal. 87-102.
  • Show author(s) (2008). Anticancer Immunotherapy in Combination with Proapoptotic Therapy. Current Cancer Drug Targets. 666-675.
  • Show author(s) (2007). Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert opinion on therapeutic targets. 1055-1069.
  • Show author(s) (2007). Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology. 344-354.
  • Show author(s) (2007). Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert Review of Anticancer Therapy. 741-751.
  • Show author(s) (2006). Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert opinion on therapeutic targets. 51-68.
  • Show author(s) (2006). Immunotherapy in chronic lymphocytic leukemia. Cancer Immunology and Immunotherapy. 185-187.
  • Show author(s) (2005). Proteomics in acute myelogenous leukaemia (AML): Methodological strategies-and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 631-646.
  • Show author(s) (2005). Antiangiogenic therapy in acute myelogenous leukemia: Targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Current Cancer Drug Targets. 229-248.
  • Show author(s) (2005). Animal models of acute myelogenous leukaemia - development, application and future perspectives. Leukemia. 687-706.
  • Show author(s) (2001). Biological treatment in acute myelogenous leukemia: how should T cell targeting immunotherapy be combined with chemotherapy. Expert Opinion on Biological Therapy. 1005-1006.

More information in national current research information system (CRIStin)